These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29457927)

  • 1. Structural fingerprints, interactions, and signaling networks of RAS family proteins beyond RAS isoforms.
    Nakhaei-Rad S; Haghighi F; Nouri P; Rezaei Adariani S; Lissy J; Kazemein Jasemi NS; Dvorsky R; Ahmadian MR
    Crit Rev Biochem Mol Biol; 2018 Apr; 53(2):130-156. PubMed ID: 29457927
    [No Abstract]   [Full Text] [Related]  

  • 2. The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects.
    Johnson CW; Reid D; Parker JA; Salter S; Knihtila R; Kuzmic P; Mattos C
    J Biol Chem; 2017 Aug; 292(31):12981-12993. PubMed ID: 28630043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions.
    Nakhaeizadeh H; Amin E; Nakhaei-Rad S; Dvorsky R; Ahmadian MR
    PLoS One; 2016; 11(12):e0167145. PubMed ID: 27936046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The spatiotemporal regulation of RAS signalling.
    Herrero A; Matallanas D; Kolch W
    Biochem Soc Trans; 2016 Oct; 44(5):1517-1522. PubMed ID: 27911734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The K-Ras, N-Ras, and H-Ras Isoforms: Unique Conformational Preferences and Implications for Targeting Oncogenic Mutants.
    Parker JA; Mattos C
    Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29038336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
    Nussinov R; Zhang M; Tsai CJ; Jang H
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GTP-binding proteins as oncogenes in human tumors.
    McCormick F
    Environ Health Perspect; 1991 Jun; 93():17-8. PubMed ID: 1773789
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Nelson AC; Turbyville TJ; Dharmaiah S; Rigby M; Yang R; Wang TY; Columbus J; Stephens R; Taylor T; Sciacca D; Onsongo G; Sarver A; Subramanian S; Nissley DV; Simanshu DK; Lou E
    J Biol Chem; 2020 Jul; 295(28):9335-9348. PubMed ID: 32393580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of liver oncogenic potential among human RAS isoforms.
    Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
    Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulators and effectors of ras proteins.
    Bollag G; McCormick F
    Annu Rev Cell Biol; 1991; 7():601-32. PubMed ID: 1667084
    [No Abstract]   [Full Text] [Related]  

  • 11. Wild-type RAS: keeping mutant RAS in CHK.
    Anastassiadis T; Brown EJ
    Cancer Cell; 2014 Feb; 25(2):137-8. PubMed ID: 24525230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS Alleles: The Devil Is in the Detail.
    Haigis KM
    Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capturing RAS oligomerization on a membrane.
    Yun SD; Scott E; Chang JY; Bahramimoghaddam H; Lynn M; Lantz C; Russell DH; Laganowsky A
    Proc Natl Acad Sci U S A; 2024 Aug; 121(34):e2405986121. PubMed ID: 39145928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.
    Huang X; Schwind S; Santhanam R; Eisfeld AK; Chiang CL; Lankenau M; Yu B; Hoellerbauer P; Jin Y; Tarighat SS; Khalife J; Walker A; Perrotti D; Bloomfield CD; Wang H; Lee RJ; Lee LJ; Marcucci G
    Oncotarget; 2016 Sep; 7(37):59273-59286. PubMed ID: 27517749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.
    Shin SM; Choi DK; Jung K; Bae J; Kim JS; Park SW; Song KH; Kim YS
    Nat Commun; 2017 May; 8():15090. PubMed ID: 28489072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
    Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
    Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Heterogeneity of Ras GTPase-activating proteins].
    Hattori S
    Seikagaku; 1994 Oct; 66(10):1331-5. PubMed ID: 7829928
    [No Abstract]   [Full Text] [Related]  

  • 20. Anthraquinones as Inhibitors of SOS RAS-GEF Activity.
    Fernández-Medarde A; Fuentes-Mateos R; García-Navas R; Juan AO; Sánchez-López JM; Fernández-Medarde A; Santos E
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.